Venlafaxine Hcl Capsule, Extended Release
Product Images NDC 80425-0194

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hcl (NDC 80425-0194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

FDA Label Image

Graph 1 (Graph 1)

Graph 1 (Graph 1)
This text appears to be a list of drug interactions and their effects on the analyte venlafaxine. The list includes the interacting drugs ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium. The table provides recommendations for PK Fold Change and 90% CI. The bottom of the text provides recommendations for avoiding concomitant use or using with caution, as well as information on dose adjustment and potential clinical significance.*
FDA Label Image

Graph 3 (Graph 3)

Graph 3 (Graph 3)
This appears to be a table or chart showing recommendations for adjusting doses of the drug venlafaxine based on different factors such as hepatic or renal impairment, age, and gender. It includes specific recommendations for reducing doses by certain percentages and individualizing dosing.*
FDA Label Image

Graph 2 (Graphh 2)

Graph 2 (Graphh 2)
This is a drug interaction table that lists different drugs and their effects when taken together. The table includes information on the PKFold change and 90% CI recommendation, Cmax, AUC, and recommended actions to take when using the drugs in combination. The drugs listed include ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium. The recommendations include avoiding concomitant use, no dose adjustment needed, and using caution and monitoring blood pressure.*
FDA Label Image

Label 1 (Label 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.